BOTANIX PHARMACEUTICALS LIMITED (BOT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BOT - BOTANIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0.4

Index: ASX300 | ALL-ORDS

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.11 11 Sep 2025	0.000 OPEN $0.11	0.000 HIGH $0.12	15,214,001 LOW $0.11

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$0.11

11 Sep
2025

0.000

OPEN

$0.11

0.000

HIGH

$0.12

15,214,001

LOW

$0.11

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	-4.7
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	6.5 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	4.1
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-78.6 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-1,332.69 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-90.93 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-81.16 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-71.53 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-90.93 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-74.68 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-78.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	9 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	23 M
Total Debt	xxx	xxx	xxx	xxx	xxx	32 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	65 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	7.72

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	1.0 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	16.19 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	78 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	12 M
Research & Development	xxx	xxx	xxx	xxx	xxx	0 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Canaccord Genuity	08/09/2025	1	Buy	$0.27	145.45%	Botanix Pharmaceuticals is in a holding patter as investors await stronger Sofdra traction, says Canaccord Genuity. Sofdra is a topical gel developed for treating primary axillary hyperhidrosis, or excessive underarm sweating. The broker notes 30 sales reps are converting patients at expected rates, supporting forecast script growth. Profitability is expected by 2Q27. FY25 revenue of $5.8m was driven by Sofdra sales, with 16,689 prescriptions at a 20% gross-to-net yield. Operating expenses were -$94.1m, slightly worse than the broker's forecasts, leading to a -$86.4m loss. Botanix ended FY25 with $65m in cash after a $40m raise. The broker sees the next two quarters as critical for market trust. A Buy rating and 27c target price are retained. FORECAST Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents. Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.60 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Canaccord Genuity

08/09/2025

Buy

$0.27

145.45%

Botanix Pharmaceuticals is in a holding patter as investors await stronger Sofdra traction, says Canaccord Genuity. Sofdra is a topical gel developed for treating primary axillary hyperhidrosis, or excessive underarm sweating.

The broker notes 30 sales reps are converting patients at expected rates, supporting forecast script growth. Profitability is expected by 2Q27.

FY25 revenue of $5.8m was driven by Sofdra sales, with 16,689 prescriptions at a 20% gross-to-net yield. Operating expenses were -$94.1m, slightly worse than the broker's forecasts, leading to a -$86.4m loss.

Botanix ended FY25 with $65m in cash after a $40m raise.

The broker sees the next two quarters as critical for market trust. A Buy rating and 27c target price are retained.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.60 cents.

Access Extra Coverage Research History >

BOT STOCK CHART

FNArena News on BOT

1	Australian Broker Call Extra Edition – Sep 09, 2025 Sep 09 2025 - Daily Market Reports

2	Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More Sep 04 2025 - Rudi's View

3	Australian Broker Call Extra Edition – Jul 31, 2025 Jul 31 2025 - Daily Market Reports

4	Next Week At A Glance – 22-24 Apr 2025 Apr 17 2025 - Weekly Reports

5	Spotlight On ASX-Listed Cannabis Companies Jan 31 2024 - Small Caps

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Earnings Result Leaves CSL Bloodied Aug 21 2025 - Australia

2	Renewed Momentum For CSL Shares Jul 22 2025 - Technicals

3	Treasure Chest: CSL Not A One-Trick Pony Jul 14 2025 - Treasure Chest

4	The Enigma Surrounding Clinuvel Jul 03 2025 - Small Caps

5	Rudi’s View: CSL & NextDC May 08 2025 - Rudi's View

6	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

7	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

8	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

9	Dr Boreham’s Crucible: Aroa Biosurgery Jul 29 2024 - Small Caps

10	CSL Shares Breaking Free Jul 23 2024 - Technicals

Get 2 Weeks free trial

Sign Up

Member Login

BOTANIX PHARMACEUTICALS LIMITED (BOT)
Share Price Analysis and Chart